Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
4628
Study information
Scientific title
A non-randomised observational trial in participants with primary osteoarthritis who will be used for mapping osteoarthritis susceptibility genes by genome-wide association scan
Acronym
arcOGEN
Study hypothesis
A collection of participants with primary osteoarthritis who will be used for mapping osteoarthritis susceptibility genes by genome-wide association scan and by other genetic approaches.
Ethics approval
Oxfordshire Research Ethics Committee (REC) C approved on the 3rd January 2008 (ref: 07/H0606/150)
Study design
Non-randomised observational trial in primary, secondary and tertiary centres
Primary study design
Observational
Secondary study design
Multi-centre
Trial setting
Other
Trial type
Screening
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
Topic: Musculoskeletal; Subtopic: Musculoskeletal (all Subtopics); Disease: Musculoskeletal
Intervention
There is no intervention in this trial. Recruited participants have a blood sample taken for a DNA test and a questionnaire will be answered. No treatments are given.
Intervention type
Other
Phase
Not Applicable
Drug names
Primary outcome measure
Questionnaire, completed at time of blood sampling
Secondary outcome measures
No secondary outcome measures
Overall trial start date
01/03/2008
Overall trial end date
31/12/2010
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. Primary osteoarthritis ascertained by joint replacement of the hip or the knee
2. Male and female, lower age limit of 40 years
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
Planned Sample Size: 8000; UK Sample Size: 8000
Participant exclusion criteria
Secondary forms of osteoarthritis or non-osteoarthritic diseases that result in joint replacement surgery
Recruitment start date
01/03/2008
Recruitment end date
31/12/2010
Locations
Countries of recruitment
United Kingdom
Trial participating centre
The Medical School
Newcastle
NE1 4LP
United Kingdom
Sponsor information
Organisation
Newcastle upon Tyne Hospitals NHS Foundation Trust (UK)
Sponsor details
Wolfson Unit of Clinical Pharmacology
Institute of Cellular Medicine
Framlington Place
Newcastle
NE2 4HH
United Kingdom
Sponsor type
Hospital/treatment centre
Website
Funders
Funder type
Charity
Funder name
Arthritis Research Campaign (ARC) (UK)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Basic results (scientific)
Publication list
2011 results in: http://www.ncbi.nlm.nih.gov/pubmed/21177295
2012 results in: http://www.ncbi.nlm.nih.gov/pubmed/22763110
Publication citations
-
Results
Panoutsopoulou K, Southam L, Elliott KS, Wrayner N, Zhai G, Beazley C, Thorleifsson G, Arden NK, Carr A, Chapman K, Deloukas P, Doherty M, McCaskie A, Ollier WE, Ralston SH, Spector TD, Valdes AM, Wallis GA, Wilkinson JM, Arden E, Battley K, Blackburn H, Blanco FJ, Bumpstead S, Cupples LA, Day-Williams AG, Dixon K, Doherty SA, Esko T, Evangelou E, Felson D, Gomez-Reino JJ, Gonzalez A, Gordon A, Gwilliam R, Halldorsson BV, Hauksson VB, Hofman A, Hunt SE, Ioannidis JP, Ingvarsson T, Jonsdottir I, Jonsson H, Keen R, Kerkhof HJ, Kloppenburg MG, Koller N, Lakenberg N, Lane NE, Lee AT, Metspalu A, Meulenbelt I, Nevitt MC, O'Neill F, Parimi N, Potter SC, Rego-Perez I, Riancho JA, Sherburn K, Slagboom PE, Stefansson K, Styrkarsdottir U, Sumillera M, Swift D, Thorsteinsdottir U, Tsezou A, Uitterlinden AG, van Meurs JB, Watkins B, Wheeler M, Mitchell S, Zhu Y, Zmuda JM, , Zeggini E, Loughlin J, Insights into the genetic architecture of osteoarthritis from stage 1 of the arcOGEN study., Ann. Rheum. Dis., 2011, 70, 5, 864-867, doi: 10.1136/ard.2010.141473.
-
Results
, , Zeggini E, Panoutsopoulou K, Southam L, Rayner NW, Day-Williams AG, Lopes MC, Boraska V, Esko T, Evangelou E, Hoffman A, Houwing-Duistermaat JJ, Ingvarsson T, Jonsdottir I, Jonnson H, Kerkhof HJ, Kloppenburg M, Bos SD, Mangino M, Metrustry S, Slagboom PE, Thorleifsson G, Raine EV, Ratnayake M, Ricketts M, Beazley C, Blackburn H, Bumpstead S, Elliott KS, Hunt SE, Potter SC, Shin SY, Yadav VK, Zhai G, Sherburn K, Dixon K, Arden E, Aslam N, Battley PK, Carluke I, Doherty S, Gordon A, Joseph J, Keen R, Koller NC, Mitchell S, O'Neill F, Paling E, Reed MR, Rivadeneira F, Swift D, Walker K, Watkins B, Wheeler M, Birrell F, Ioannidis JP, Meulenbelt I, Metspalu A, Rai A, Salter D, Stefansson K, Stykarsdottir U, Uitterlinden AG, van Meurs JB, Chapman K, Deloukas P, Ollier WE, Wallis GA, Arden N, Carr A, Doherty M, McCaskie A, Willkinson JM, Ralston SH, Valdes AM, Spector TD, Loughlin J, Identification of new susceptibility loci for osteoarthritis (arcOGEN): a genome-wide association study., Lancet, 2012, 380, 9844, 815-823, doi: 10.1016/S0140-6736(12)60681-3.